For Renal Cell Carcinoma, Duration of Sunitinib Treatment Shorter with Renal Insufficiency

Share this content:

the Cancer Therapy Advisor take:

First-line targeted therapy with sunitinib in patients with metastatic renal cell carcinoma (mRCC) is significantly shorter in patients with renal insufficiency (RI), according to a recent study published in the European Journal of Cancer.

In a retrospective, registry-based study, Alexandr Poprach, PhD, of Masaryk Memorial Cancer Institute in the Czech Republic and fellow researchers looked at a cohort of 790 patients treated with sunitinib from 2006 to 2013. At initiation, 22 patients had severe RI, 234 had moderate RI, and 534 had mild to normal RI.

The researchers found that median progression-free survival rates among the three groups (severe, moderate, and mild-to-normal) was 5.3 months, 8.1 months, and 11.3 months, as well as median overall survival rates being 26.3 months, 21.2 months, and 26.3 months, respectively.

Additionally, disease control rates were 45.5 percent, 56.4 percent, and 59.2 percent, respectively. They found no unexpected toxicities in patients with RI, but treatment was more frequently discontinued due to adverse events in these patients, leading to a much shorter duration of therapy.

“These results highlight the need for optimal management of side-effects in patients with mRCC and RI,” the authors concluded.

Autologous Immunotherapy for mRCC Shows Promise
Sunitinib duration in patients with mRCC is significantly shorter in patients with renal insufficiency.
The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI). Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters